Reported effects of the COVID-19 pandemic on the psychological status of emergency healthcare workers: A scoping review


Posted: 2021-11-22 20:00:00
Background: While literature on psychological consequences among frontline healthcare workers (HCWs) flourishes, understanding the psychological burden on this group is particularly crucial, as their exposure to COVID-19 makes them especially at high risk. We explored what is known about psychological effects of the COVID-19 pandemic on emergency HCWs. Methods: We used a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. Results: The search identified 5432 articles, from which a total of 21 were included in the final review. Anxiety, burnout, depression, inadequate sleep, post-traumatic stress disorder (PTSD) symptoms, distress/stress and secondary trauma, were all reportedly experienced by emergency HCWs. Anxiety, burnout, depression and stress levels were higher among physicians and nurses compared to others. Post-traumatic stress disorder symptoms were higher among reserve medics, while Red Cross volunteers developed similar reactions of psychological stress and secondary trauma to other healthcare workers. Male HCWs reported more post-traumatic stress disorder symptoms than females, while stress was higher among females than male HCWs. Conclusions: Emergency HCWs providing care during the COVID-19 pandemic are at risk from specific psychological impacts, including anxiety, burnout, depression, inadequate sleep, PTSD symptoms, psychological distress/stress and secondary trauma, and stress TWEETABLE ABSTRACT: Emergency healthcare workers are at direct risk of psychological impacts from the COVID-19 pandemic. Keywords: COVID-19; Emergency; Healthcare worker; Mental health; Psychological impact; Scoping review.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
3月 27, 2020 バイオアソシエイツ

COVID-19治験ワクチンのNIH臨床試験が始まる。ワクチンはウイルスのスパイクタンパク質をコードするmRNA。

シアナのカイザーパーマネンテワシントン健康研究所(KPWHRI)で、コロナウイルス2019(COVID-19)を予防するために設計された治験ワクチンを評価する第1相臨床試験が始った。国立衛生研究所の一部である国立アレルギー感染症研究所(NIAID)が試験に資金を提供している。KPWHRIはNIAIDの感染症臨床研究コンソーシアムの一部だ。このオープンラベル試験では、18歳から55歳までのシアトルを拠点とする45人の健康な成人ボランティアが約6週間に渡り協力する。2020年3月16日に治験ワクチンを最初の参加者に接種…

ゲスト 543人 と メンバー 2人 がオンラインです